{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', '3.3.', 'Exploratory Enppoints', 'Change in the following in the treatment period:', 'Treatment Satisfaction Questionnaire for Medication (TSQM) domain scores', 'Hemophilia Activities List (HAL) score', 'Pediatric HAL (pedHAL) score', 'EuroQol-5 dimension (EQ-5D) score', 'Hemophilia Quality of Life Questionnaire for children and adolescents', '(Haemo-QOL) score', 'Hemophilia Joint Health Score (HJHS)', 'Number of target joint bleeding episodes', 'Incidence and titer of antidrug antibodies to fitusiran in the fitusiran treatment arm', 'AT activity level over time', 'Thrombin generation over time', 'Fitusiran plasma levels', 'Annualized weight-adjusted use of factor concentrates', 'Change in patient resource use (eg, work/school attendance, visits to doctor/hospital)', '3.4.', 'Safety Endpoint', 'Incidence, severity, seriousness, and relatedness of adverse events (AEs)', '4.', 'INVESTIGATIONAL PLAN', '4.1.', 'Summary of Study Design', 'The ATLAS A/B trial (ALN-AT3SC-004) is a multicenter, multinational, randomized,', 'open-label Phase 3 study designed to evaluate the efficacy and safety of fitusiran in male patients', 'aged >12 years with hemophilia A or B, without inhibitory antibodies to FVIII or FIX, who are', 'not receiving prophylactic therapy.', 'The study will be conducted at approximately 100 clinical study centers worldwide.', 'Property of the Sanofi Group - strictly confidential', '35', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'Eligible patients will be randomized in a 2:1 ratio to:', 'Fitusiran treatment arm: Fitusiran 80 mg administered SC as prophylaxis once', 'monthly, with use of on-demand factor concentrates for treatment of breakthrough', 'bleeding episodes', 'On-demand arm: On-demand factor concentrates for treatment of breakthrough', 'bleeding episodes', 'On-demand use of factor concentrates is defined as the use of these agents, as needed, for', 'episodic bleeding, and not on a regular regimen intended to prevent spontaneous bleeding.', 'Throughout the study, patients in the fitusiran treatment arm may receive on-demand treatment', 'for breakthrough bleeding episodes with factor concentrates, as appropriate. For patients in the', 'fitusiran treatment arm who have received at least 1 dose of fitusiran and are being treated for', 'breakthrough bleeding episodes, it is recommended to follow the guidelines provided in', 'Section 6.3.1 per Investigator discretion.', 'Bleeding events and doses of factor concentrates administered during the conduct of the study', 'will be recorded in an electronic Diary (eDiary), as described in Section 7.2.1. Since bleeding', 'episodes are recorded as an efficacy assessment of fitusiran, these will not be treated as AEs', 'unless they meet any of the SAE criteria listed in Section 7.5.6.1. Safety, quality of life,', 'pharmacodynamic, and pharmacokinetic data will also be collected.', 'All patients will be treated for a total of 9 months; patients randomized to the fitusiran treatment', 'arm will receive a total of 9 SC injections of fitusiran. Because the full PD effect of fitusiran is', 'not achieved until approximately 28 days after receiving the first dose, efficacy will be assessed', 'during the final 8 months on study (Day 29 to Month 9). Therefore, the overall fitusiran', 'treatment period is defined as the onset period (Day 1 to Day 28 after receipt of the first dose,', 'during which the AT lowering capacity of fitusiran is increasing but has not yet reached', 'therapeutic levels) plus the efficacy period (Day 29 and after, when the AT lowering capacity of', 'fitusiran has achieved therapeutic target range).', 'Patients may undergo unplanned or emergency surgery during the study, but must not schedule', 'non-urgent surgery to occur during the study. Perioperative guidance should be followed as', 'specified in Section 6.6.', 'A Study Steering Committee, composed of experts in the field of hemophilia, will advise the', 'Sponsor on study design and conduct (see Section 4.6).', 'An independent data monitoring committee (DMC) will oversee the safety and overall conduct', 'of this study as described in Section 4.7.', 'The study design schema is presented in Figure 1. Patients who complete the study may be', 'eligible for an open-label extension study in which patients coming from both the fitusiran and', 'the on-demand arms will be administered monthly SC doses of fitusiran.', 'Property of the Sanofi Group - strictly confidential', '36', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}